The development of Mab 4-1a provides a new, specific reagent for studying lipoprotein lipase without interfering with its catalytic or binding functions.
Answers are grounded in this paper and cite their sources.
Mab 4-1a offers a non-interfering LPL probe; leaves open its utility in human metabolic research.
Lipoprotein lipase (LPL) has been highly conserved through vertebrate evolution, making it challenging to generate useful antibodies. Some polyclonal antibodies against LPL have turned out to be nonspecific, and the available monoclonal antibodies (Mabs) against LPL, all of which bind to LPL's carboxyl terminus, have drawbacks for some purposes. We report a new LPL-specific monoclonal antibody, Mab 4-1a, which binds to the amino terminus of LPL (residues 5-25). Mab 4-1a binds human and bovine LPL avidly; it does not inhibit LPL catalytic activity nor does it interfere with the binding of LPL to heparin. Mab 4-1a does not bind to human hepatic lipase. Mab 4-1a binds to GPIHBP1-bound LPL and does not interfere with the ability of the LPL-GPIHBP1 complex to bind triglyceride-rich lipoproteins. Mab 4-1a will be a useful reagent for both biochemists and clinical laboratories.
No takes yet. Share an insight, caveat, or question.
Bensadoun et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: